Curative effect of two strategies of drug treatment for HbeAg -negative chronic hepatitis B

Objective To compare the curative effect of adefovir dipivoxil plus lamivudine and entecavir alone in the treatment of HbeAg-negative chronic hepatitis B.Methods A total of 276 cases of outpatients with HbeAg-negative chronic hepatitis B were divided into two groups: adefovir dipivoxil plus lamivudine group and entecavir group,treated for 24 months respectively,collected the venous blood to detect the HBV-DNA,ALT,AST and T-Bil after the treatment of 6,12 and 24 months,during follow-up,proceed the routine inspection and recorded the adverse reactions for the patients.Results The ALT,AST,T-Bil levels of two groups after treatment were significantly reduced,the regular rate of ALT in the same period between the two groups were not significant different(χ2=3.63,χ20.05(2)=5.99,χ2χ20.05(2),P 0.05);the regular rate of HBV-DNA in the same period between the two groups were not significant different(χ2=0,χ20.05(2)=5.99,χ2χ20.05(2),P 0.05),but the regular rate of HBV-DNA in entecavir group was higher than the combina tion group.Conclusion Adefovir dipivoxil plus lamivudine and entecavir alone in the treatment of HbeAg-negative chronic hepatitis B patients with lamivudine resistance are effective,but the regular rate of HBV-DNA of entecavir therapy alone have better effect than the combination therapy of adefovir dipivoxil plus lamivudine.